JP2021519262A5 - - Google Patents
Info
- Publication number
- JP2021519262A5 JP2021519262A5 JP2020551269A JP2020551269A JP2021519262A5 JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5 JP 2020551269 A JP2020551269 A JP 2020551269A JP 2020551269 A JP2020551269 A JP 2020551269A JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- use according
- indole
- pharmaceutically acceptable
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850380 | 2018-04-05 | ||
| SE1850380-5 | 2018-04-05 | ||
| PCT/SE2019/050312 WO2019194738A1 (en) | 2018-04-05 | 2019-04-04 | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519262A JP2021519262A (ja) | 2021-08-10 |
| JPWO2019194738A5 JPWO2019194738A5 (https=) | 2022-04-07 |
| JP2021519262A5 true JP2021519262A5 (https=) | 2022-04-07 |
| JP7372253B2 JP7372253B2 (ja) | 2023-10-31 |
Family
ID=68101552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551269A Active JP7372253B2 (ja) | 2018-04-05 | 2019-04-04 | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11590130B2 (https=) |
| EP (1) | EP3773592B1 (https=) |
| JP (1) | JP7372253B2 (https=) |
| CN (1) | CN111936143A (https=) |
| CA (1) | CA3095709A1 (https=) |
| WO (1) | WO2019194738A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20230006568A (ko) * | 2020-05-04 | 2023-01-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| WO2024191805A1 (en) * | 2023-03-10 | 2024-09-19 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02121B (me) | 2006-01-17 | 2014-06-30 | Abbvie Ireland Unlimited Co | Kombinovana terapija sa parp inhibitorima |
| CN101743003A (zh) | 2007-05-25 | 2010-06-16 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的chk和parp抑制剂的组合 |
| KR20100102607A (ko) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| CA2708157A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| JP5464609B2 (ja) * | 2008-03-27 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チューブリン重合阻害剤としてのキナゾリノン誘導体 |
| CA2716726C (en) * | 2008-03-27 | 2017-01-24 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| US20120130144A1 (en) | 2009-02-04 | 2012-05-24 | Bipar Sciences, Inc. | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor |
| EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| US20130131018A1 (en) | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| DK2688883T3 (en) * | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| EP2714703B1 (en) * | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| US9132120B1 (en) | 2012-04-02 | 2015-09-15 | Stc.Unm | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers |
| CA2909091C (en) | 2013-04-09 | 2021-11-02 | The Board Of Trustees Of The University Of Illinois | Tumor-selective combination therapy |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| WO2017013593A1 (en) * | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| US20180344725A1 (en) * | 2015-11-20 | 2018-12-06 | Hoyun Lee | Quinolone chalcone compounds and uses thereof |
| HUE066216T2 (hu) * | 2016-06-24 | 2024-07-28 | Univ California | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében |
-
2019
- 2019-04-04 CA CA3095709A patent/CA3095709A1/en active Pending
- 2019-04-04 US US16/981,232 patent/US11590130B2/en active Active
- 2019-04-04 CN CN201980024687.3A patent/CN111936143A/zh active Pending
- 2019-04-04 WO PCT/SE2019/050312 patent/WO2019194738A1/en not_active Ceased
- 2019-04-04 EP EP19781419.7A patent/EP3773592B1/en active Active
- 2019-04-04 JP JP2020551269A patent/JP7372253B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519262A5 (https=) | ||
| JP2013505249A5 (https=) | ||
| JP2010528026A5 (https=) | ||
| ES2670864T3 (es) | Inhibidores de histonas desmetilasas | |
| JP2015232006A5 (https=) | ||
| RU2013128612A (ru) | Соли и кристаллические формы индуцирующего апоптоз агента | |
| JP2017516784A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| HRP20171902T1 (hr) | Farmaceutski oblik za doziranje za oralnu primjenu inhibitora iz obitelji bcl-2 | |
| JP2013544804A5 (https=) | ||
| JP2011527334A5 (https=) | ||
| JP2021534168A5 (https=) | ||
| RU2012115851A (ru) | Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2 | |
| JP2015509540A5 (https=) | ||
| JP2020504716A5 (https=) | ||
| JP2021534158A5 (https=) | ||
| JP2008528671A5 (https=) | ||
| JP2014514317A5 (https=) | ||
| JP2009541223A5 (https=) | ||
| RU2011148521A (ru) | Соль авт-263 и ее формы в твердом состоянии | |
| JP2012520321A5 (https=) | ||
| JP2014530243A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2010527984A5 (https=) | ||
| JP2019511550A5 (https=) | ||
| JP2020534300A5 (https=) |